The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Drug repurposing in oncology—patient and health systems opportunities
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Propranolol for Severe Hemangiomas of Infancy
Léauté-Labrèze, C., de la Roque, E. D., Hubiche, T., Boralevi, F., Thambo, J.-B., & Taïeb, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0708819 · Cited by 2,374
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945
The sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843
Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference
Cheng, F., Liu, C., Jiang, J., Lu, W., Li, W., Liu, G., Zhou, W., Huang, J., & Tang, Y. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002503 · Cited by 818
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Dei Tos, A. P., Kunkler, I., Otter, R., Licitra, L., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 809
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
DiPersio, J. F., Stadtmauer, E. A., Nademanee, A., Micallef, I. N. M., Stiff, P. J., Kaufman, J. L., Maziarz, R. T., Hosing, C., Früehauf, S., Horwitz, M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-174946 · Cited by 789
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Birsoy, K., Possemato, R., Lorbeer, F. K., Bayraktar, E. C., Thiru, P., Yucel, B., Wang, T., Chen, W. W., Clish, C. B., & Sabatini, D. M. (2014) · Nature · doi:10.1038/nature13110 · Cited by 710
Schultz, K. R., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Wang, C., Davies, S. M., Gaynon, P. S., Trigg, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2514 · Cited by 701
DiPersio, J. F., Micallef, I. N., Stiff, P. J., Bolwell, B. J., Maziarz, R. T., Jacobsen, E. D., Nademanee, A. P., McCarty, J. M., Bridger, G. J., & Calandra, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7209 · Cited by 680
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Withrow & Macewen's Small Animal Clinical Oncology
Withrow, S. J., Vail, D. M., & Page, R. L. (2019) · Medical Entomology and Zoology · Cited by 637
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2030 · Cited by 629
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Sotelo, J., Briceño, E., & López-González, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00008 · Cited by 505
Intratumor Heterogeneity: Seeing the Wood for the Trees
Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L., & Swanton, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003854 · Cited by 490
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Cole, B. F., Logan, R. F., Halabi, S., Benamouzig, R., Sandler, R. S., Grainge, M. J., Chaussade, S., & Baron, J. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn485 · Cited by 476
De Clercq, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1134 · Cited by 460
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M., & Soyuer, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00871.x · Cited by 455
Powe, D. G., Voss, M. J., Zänker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., & Entschladen, F. (2010) · Oncotarget · doi:10.18632/oncotarget.197 · Cited by 453
The Anatomy of Medical Research: US and International Comparisons
Moses, H., Matheson, D. H. M., Cairns-Smith, S., George, B. P., Palisch, C., & Dorsey, E. R. (2015) · JAMA · doi:10.1001/jama.2014.15939 · Cited by 446
Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
Cohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Withrow and MacEwen's Small Animal Clinical Oncology
(2013) · Elsevier eBooks · doi:10.1016/c2009-0-53135-2 · Cited by 415
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T., Khedkar, S., & Rigby, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 407
Estimates of benefits and harms of prophylactic use of aspirin in the general population
Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu225 · Cited by 382
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., Zmoos, A.-F., Vaka, D., Tran, K. Q. T., Zhou, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0183 · Cited by 358
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent
Pantziarka, P. (2014) · ecancermedicalscience · doi:10.3332/ecancer.2014.485 · Cited by 280
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Prost, S., Relouzat, F., Spentchian, M., Ouzegdouh, Y., Saliba, J., Massonnet, G., Beressi, J.-P., Verhoeyen, E., Raggueneau, V., Maneglier, B., et al. (2015) · Nature · doi:10.1038/nature15248 · Cited by 272
Janzer, A., German, N. J., Gonzalez-Herrera, K. N., Asara, J. M., Haigis, M. C., & Struhl, K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409844111 · Cited by 265
Shakhar, G., & Ben‐Eliyahu, S. (1998) · PubMed · Cited by 253
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC
Blandino, G., Valerio, M., Cioce, M., Mori, F., Casadei, L., Pulito, C., Sacconi, A., Biagioni, F., Cortese, G., Galanti, S., et al. (2012) · Nature Communications · doi:10.1038/ncomms1859 · Cited by 242
Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations
Flynn, P., Miller, W., Weisdorf, D., Arthur, D., Brunning, R., & Branda, R. (1983) · Blood · doi:10.1182/blood.v62.6.1211.1211 · Cited by 240
Glasner, A., Avraham, R., Rosenne, E., Benish, M., Zmora, O., Shemer, S., Meiboom, H., & Ben-Eliyahu, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903301 · Cited by 239
Dagher, R., Cohen, M., Williams, G., et al. (2002) · PubMed · Cited by 237
Pasquier, E., Ciccolini, J., Carre, M., Giacometti, S., Fanciullino, R., Pouchy, C., Montero, M.-P., Serdjebi, C., Kavallaris, M., & André, N. (2011) · Oncotarget · doi:10.18632/oncotarget.343 · Cited by 234
Shakhar, G., & Ben-Eliyahu, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3251 · Cited by 231
Boguski, M. S., Mandl, K. D., & Sukhatme, V. P. (2009) · Science · doi:10.1126/science.1169920 · Cited by 220
Self-citationDomingo, E., Church, D. N., Sieber, O., Ramamoorthy, R., Yanagisawa, Y., Johnstone, E., Davidson, B., Kerr, D. J., Tomlinson, I. P. M., & Midgley, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.0322 · Cited by 210
Association of Aspirin and NSAID Use With Risk of Colorectal Cancer According to Genetic Variants
Nan, H., Hutter, C. M., Lin, Y., Jacobs, E. J., Ulrich, C. M., White, E., Baron, J. A., Berndt, S. I., Brenner, H., Butterbach, K., et al. (2015) · JAMA · doi:10.1001/jama.2015.1815 · Cited by 204
Nechushtan, H., Hamamreh, Y., Nidal, S., Gotfried, M., Baron, A., Shalev, Y. I., Nisman, B., Peretz, T., & Peylan-Ramu, N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0424 · Cited by 202
Metformin in Breast Cancer: Time for Action
Goodwin, P. J., Ligibel, J. A., & Stambolic, V. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1630 · Cited by 200
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 192
In silico drug repositioning – what we need to know
Liu, Z., Fang, H., Reagan, K., Xu, X., Mendrick, D. L., Slikker, W., & Tong, W. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.005 · Cited by 183
Thalidomide and dexamethasone for resistant multiple myeloma
Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K., & Alexanian, R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04345.x · Cited by 177
Has the time come for metronomics in low-income and middle-income countries?
André, N., Banavali, S., Snihur, Y., & Pasquier, E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70056-1 · Cited by 174
Sydes, M. R., Parmar, M. K., Mason, M. D., Clarke, N. W., Amos, C., Anderson, J., de Bono, J., Dearnaley, D. P., Dwyer, J., Green, C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-168 · Cited by 174
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.442 · Cited by 173
Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., Okazaki, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0436 · Cited by 170
Elmslie, R. E., Glawe, P., & Dow, S. W. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.0179.x · Cited by 169
Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma
De Giorgi, V., Grazzini, M., Gandini, S., Benemei, S., Lotti, T., Marchionni, N., & Geppetti, P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.131 · Cited by 167
Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status
Nishihara, R., Lochhead, P., Kuchiba, A., Jung, S., Yamauchi, M., Liao, X., Imamura, Y., Qian, Z. R., Morikawa, T., Wang, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6599 · Cited by 166
Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors
Röhrig, U. F., Awad, L., Grosdidier, A., Larrieu, P., Stroobant, V., Colau, D., Cerundolo, V., Simpson, A. J. G., Vogel, P., Van den Eynde, B. J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9014718 · Cited by 163
Pasquier, E., Street, J., Pouchy, C., Carre, M., Gifford, A. J., Murray, J., Norris, M. D., Trahair, T., Andre, N., & Kavallaris, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.205 · Cited by 162
Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates
Gronich, N., & Rennert, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.169 · Cited by 161
Unlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R. D., Aftab, B. T., Huang, P., & Liu, J. O. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c3950 · Cited by 157
Orecchioni, S., Reggiani, F., Talarico, G., Mancuso, P., Calleri, A., Gregato, G., Labanca, V., Noonan, D. M., Dallaglio, K., Albini, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29193 · Cited by 155
Self-citationChronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling
Lamkin, D. M., Sloan, E. K., Patel, A. J., Chiang, B. S., Pimentel, M. A., Ma, J. C. Y., Arevalo, J. M. G., Morizono, K., & Cole, S. W. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.01.013 · Cited by 148
OECD Information Technology Outlook 2008
OECD (2008) · OECD information technology outlook · doi:10.1787/it_outlook-2008-en · Cited by 146
Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors
Dienstmann, R., Jang, I. S., Bot, B. M., Friend, S. H., & Guinney, J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1118 · Cited by 143
The major role of clinicians in the discovery of off-label drug therapies
DeMonaco, H. J., Ali, A., & von Hippel, E. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.323 · Cited by 142
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Dimopoulos, M. A., Anagnostopoulos, A., & Weber, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.200 · Cited by 137
Chaudhary, S., Bansal, C., Ranga, U., & Singh, K. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2013.337 · Cited by 133
Ishikawa, H., Mutoh, M., Suzuki, S., Tokudome, S., Saida, Y., Abe, T., Okamura, S., Tajika, M., Joh, T., Tanaka, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305827 · Cited by 131
More multiarm randomised trials of superiority are needed
Parmar, M. K. B., Carpenter, J., & Sydes, M. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61122-3 · Cited by 127
Fink, S. P., Yamauchi, M., Nishihara, R., Jung, S., Kuchiba, A., Wu, K., Cho, E., Giovannucci, E. L., Fuchs, C. S., Ogino, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008481 · Cited by 124
Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme
Briceño, E., Calderón, A., & Sotelo, J. (2007) · Surgical Neurology · doi:10.1016/j.surneu.2006.08.080 · Cited by 124
Belpomme, D., Gauthier, S., Pujade-Lauraine, É., Facchini, T., Goudier, M.-J., Krakowski, I., Netter-Pinon, G., Frénay, M., Gousset, C., MARIE, F.-N., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026556119020 · Cited by 118
Antitumour immunity gets a boost
Wolchok, J. D., & Chan, T. A.-T. (2014) · Nature · doi:10.1038/515496a · Cited by 113
Orecchioni, S., Gregato, G., Martín-Padura, I., Reggiani, F., Braidotti, P., Mancuso, P., Calleri, A., Quarna, J., Marighetti, P., Aldeni, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0821 · Cited by 112
Self-citationCollins, F. S. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3461 · Cited by 109
Unfinished business: target-based drug discovery
Brown, D. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.017 · Cited by 98
Lou, Y., Peng, W., Cao, Y. L., Cao, D., Xie, J., & Li, H. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12235 · Cited by 95
Daily Aspirin Use and Cancer Mortality in a Large US Cohort
Jacobs, E. J., Newton, C. C., Gapstur, S. M., & Thun, M. J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs318 · Cited by 94
Amelio, I., Gostev, M., Knight, R. A., Willis, A. E., Melino, G., & Antonov, A. V. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.9 · Cited by 93
Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study
Dufour, P., Lang, J.-M., Giron, C., Duclos, B., Haehnel, P., Jaeck, D., Jung, J. M., & Oberling, F. (1993) · Biotherapy · doi:10.1007/bf01877380 · Cited by 86
Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
Nuffel, A. M. T. V. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.513 · Cited by 86
Nygren, P., & Larsson, R. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.844359 · Cited by 83
A review of the history, properties, and use of the immunomodulatory compound lenalidomide
Zeldis, J. B., Knight, R., Hussein, M. A., Chopra, R., & Muller, G. W. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05974.x · Cited by 80
Villoutreix, B. O., Lagorce, D., Labbé, C. M., Spérandio, O., & Miteva, M. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.06.013 · Cited by 75
Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Zerbini, L. F., Bhasin, M., de Vasconcellos, J. F., Paccez, J. D., Gu, X., Kung, A. L., & Libermann, T. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0750 · Cited by 70
García‐Sánz, R., González-Fraile, M. I., Sierra, M., López, C., González, M., & Miguel, J. F. S. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200150 · Cited by 67
Mikasa, K., Sawaki, M., Kita, E., Hamada, K., Teramoto, S., Sakamoto, M., Maeda, K., Konishi, M., & Narita, N. (2009) · Chemotherapy · doi:10.1159/000239580 · Cited by 66
Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs
Barratt, M. J., & Frail, D. E. (2012) · Cited by 64
Murteira, S., Millier, A., Ghezaiel, Z., & Lamure, M. P. (2014) · Journal of Market Access & Health Policy · doi:10.3402/jmahp.v2.22813 · Cited by 57
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer
Deva, S., & Jameson, M. B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007814.pub2 · Cited by 53
Predictive methods in drug repurposing: gold mine or just a bigger haystack?
Cavalla, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.009 · Cited by 52
Wang, H., Liu, Y., Wang, X., Liu, D., Sun, Z., Wang, C., Jin, G., Zhang, B., & Yu, S. (2015) · Cancer · doi:10.1002/cncr.29456 · Cited by 49
Drug repurposing in pediatrics and pediatric hematology oncology
Blatt, J., & Corey, S. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.009 · Cited by 48
Zhang, L., He, M., Zhang, Y., Nilubol, N., Shen, M., & Kebebew, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2671 · Cited by 46
Metformin Use and Lung Cancer Risk in Patients with Diabetes
Sakoda, L. C., Ferrara, A. M., Achacoso, N. S., Peng, T., Ehrlich, S. F., Quesenberry, C. P., & Habel, L. A. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0291 · Cited by 44
Use of Crowdsourcing for Cancer Clinical Trial Development
Leiter, A., Sablinski, T., Diefenbach, M. A., Foster, M., Greenberg, A. M., Holland, J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju258 · Cited by 43
Hermo, G. A., Torres, P. A., Ripoll, G. V., Scursoni, A. M., Gomez, D. E., Alonso, D. F., & Gobello, C. (2007) · The Veterinary Journal · doi:10.1016/j.tvjl.2007.06.015 · Cited by 41
New sources of drugs for hematologic malignancies
Sukhai, M. A., Spagnuolo, P. A., Weir, S. J., Kasper, J. M., Patton, L., & Schimmer, A. D. (2011) · Blood · doi:10.1182/blood-2011-02-315283 · Cited by 41
Dingemans, A. C., Groen, H. J. M., Herder, G. J. M., Stigt, J. A., Smit, E. F., Bahce, I., Burgers, J. A., van den Borne, B. E. E. M., Biesma, B., Vincent, A. D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv370 · Cited by 41
Reinmuth, N., Meyer, A. A., Hartwigsen, D., Schaeper, C., Huebner, G., Skock-Lober, R., Bier, A., Gerecke, U., Held, C. P., & Reck, M. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.01.001 · Cited by 37
Davidson, A., Veillard, A.-S., Tognela, A., Chan, M. M. K., Hughes, B. G. M., Boyer, M. J., Briscoe, K. P., Begbie, S. D., Abdi, E. A., Crombie, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv373 · Cited by 37
Hart, C., Vogelhuber, M., Wolff, D., Klobuch, S., Ghibelli, L., Foell, J. L., Corbacioglu, S., Rehe, K., Haegeman, G., Thomas, S., et al. (2015) · Cancer Microenvironment · doi:10.1007/s12307-015-0170-1 · Cited by 27
Discovery and Exploitation of Novel Targets by Approved Drugs
Dirix, L. Y. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7118 · Cited by 23
Mercurio, S., Padovani, L., Colin, C., Carré, M., Tchoghandjian, A., Scavarda, D., Lambert, S. R., Baeza, N., Fernandez, C., Chappé, C., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-17 · Cited by 19
Rickles, R. J., Tam, W. F., Giordano, T. P., Pierce, L. T., Farwell, M., McMillin, D. W., Necheva, A. S., CROWE, D. F., Chen, M., Avery, W., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0925 · Cited by 19
Arrowsmith, J. E., & Harrison, R. (2012) · Wiley eBooks · doi:10.1002/9781118274408.ch1 · Cited by 18
Roix, J. J., Harrison, S. D., Rainbolt, E. A., Meshaw, K. R., McMurry, A. S., Cheung, P., & Saha, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101708 · Cited by 15
Drug Development Costs Jump to $2.6 Billion
(2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2014-188 · Cited by 9
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Chang, Y., Park, H., Yang, H.-J., Lee, S., Lee, K.-Y., Kim, T. S., Jung, J., & Shin, J.-M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27214-6 · Cited by 320
Hernandez, J. J., Pryszlak, M., Smith, L., Yanchus, C., Kurji, N., Shahani, V. M., & Molinski, S. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00273 · Cited by 281
Vennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Melenec, P., Walters, S. N., del Monte-Nieto, G., Conway, J. R. W., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8504 · Cited by 267
Metadata
- Authors
- Bertolini, F., Sukhatme, V. P., & Bouche, G.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-10-20
- Volume
- 12
- Issue
- 12
- Pages
- 732-742
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2176184837
- Cited by
- 294
- References
- 136
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.